Elanco Animal Health (NYSE:ELAN) Downgraded to Hold Rating by Zacks Research

Zacks Research lowered shares of Elanco Animal Health (NYSE:ELAN) from a strong-buy rating to a hold rating in a research report sent to investors on Thursday,Zacks.com reports.

Several other equities research analysts have also recently weighed in on the stock. JPMorgan Chase & Co. raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their price target for the company from $18.00 to $24.00 in a research report on Tuesday, October 7th. Leerink Partnrs upgraded shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 17th. Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 2nd. Piper Sandler boosted their price target on Elanco Animal Health from $12.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, August 11th. Finally, Stifel Nicolaus upped their price target on Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.29.

Elanco Animal Health Trading Down 0.1%

ELAN traded down $0.03 on Thursday, hitting $21.50. 7,196,389 shares of the company were exchanged, compared to its average volume of 5,550,582. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.40 and a current ratio of 2.40. The firm has a fifty day simple moving average of $20.17 and a two-hundred day simple moving average of $16.16. The stock has a market capitalization of $10.68 billion, a PE ratio of 358.31, a price-to-earnings-growth ratio of 3.24 and a beta of 1.71. Elanco Animal Health has a 12 month low of $8.02 and a 12 month high of $22.98.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The firm had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same quarter in the prior year, the firm posted $0.13 earnings per share. The business’s quarterly revenue was up 10.4% compared to the same quarter last year. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. Sell-side analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ELAN. Allworth Financial LP grew its stake in Elanco Animal Health by 791.7% in the first quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock worth $25,000 after purchasing an additional 2,090 shares during the period. SJS Investment Consulting Inc. boosted its holdings in shares of Elanco Animal Health by 2,563.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after buying an additional 1,333 shares in the last quarter. Whittier Trust Co. of Nevada Inc. boosted its holdings in shares of Elanco Animal Health by 80.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after buying an additional 900 shares in the last quarter. Farther Finance Advisors LLC grew its position in shares of Elanco Animal Health by 79.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after buying an additional 951 shares during the period. Finally, First Horizon Advisors Inc. grew its position in shares of Elanco Animal Health by 184.3% in the 2nd quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock worth $53,000 after buying an additional 2,414 shares during the period. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.